The EU Commission sends a Statement of Objections to a pharmaceutical company over abusive patent filings and disparagement of generic competitors (Teva)

On 10 October 2022, the European Commission (the “Commission”) announced that it had sent a Statement of Objections to Teva, a pharmaceutical company marketing Copaxone®, a medicine indicated for the treatment of specific forms of multiple sclerosis. The Statement of Objections

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Quotation

Steve Ross, Peter L'Ecluse, The EU Commission sends a Statement of Objections to a pharmaceutical company over abusive patent filings and disparagement of generic competitors (Teva), 10 October 2022, e-Competitions November 2022 - II, Art. N° 109413

Visites 42

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues